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Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data Not stated.
Number of primary studies included
Five studies and two databases.
Methods of combining primary studies
Narrative method.
Investigation of differences between primary studies
Results of the review
The 5-year relapse-free survival rate on IFN was 37% versus 26% for observation and the 5-year survival rate was 46% on IFN compared with 37% on observation.
Methods used to derive estimates of effectiveness
Some of the estimates of effectiveness were based on the authors' assumptions.
Estimates of effectiveness and key assumptions
The authors assumed that the average survival from relapse to death was constant over time.
Measure of benefits used in the economic analysis
Survival, life years gained and quality-adjusted survival were the outcomes used in the economic analysis.
Direct costs
Costs were discounted at a 3% discount rate. Only health care system costs were considered. Treatment costs were based on the 1996 wholesale price of IFN and expert panel estimates of all other treatment associated costs. This included all professional, nursing and laboratory-monitoring costs, costs of scheduled visits required for treatment, and those necessitated by treatment toxicity, for patients until relapse. These costs were based, not on charges, but on costs using the projected frequency of these events in the trial as estimated by participants at two major study sites. Savings from avoiding recurrent melanoma treatment were estimated based on the opinion of an expert panel on a per month of care basis.
